-
Mashup Score: 3
A systematic review and meta-analysis found that neoadjuvant chemoimmunotherapy was associated with improved event-free survival and pathologic complete response compared with neoadjuvant chemotherapy…
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
As reported in The Lancet Oncology by Egbert F. Smit, MD, and colleagues, primary analysis in the HER2-overexpressing unresectable or metastatic non–small cell cancer (NSCLC) cohorts of the phase II DESTINY-Lung01 trial show activity of fam-trastuzumab deruxtecan-nxki (T-DXd) in this setting. Given the low antitumor activity of existing treatment options in this patient population, [T-DXd] might have the potential to fill a large unmet need in HER2-overexpressing NSCLC. — Egbert F. Smit, MD, and colleagues
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 36
Combination immunotherapy with the anti–PD-L1 monoclonal antibody durvalumab and other novel agents seemed to outperform durvalumab alone in the neoadjuvant setting for early-stage non–small cell lung cancer (NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center, Hous ton. The findings, published in Cancer Discovery, 1 were first presented at the 2022 American Association for Cancer Research Annual Meeting. The multicenter, randomized phase II NeoCOAST clinical trial
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 22
Combination immunotherapy with the anti–PD-L1 monoclonal antibody durvalumab and other novel agents seemed to outperform durvalumab alone in the neoadjuvant setting for early-stage non–small cell lung cancer (NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center, Hous ton. The findings, published in Cancer Discovery, 1 were first presented at the 2022 American Association for Cancer Research Annual Meeting. The multicenter, randomized phase II NeoCOAST clinical trial
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
In a U.S. Food and Drug Administration (FDA) pooled analysis reported in The Lancet Oncology, Bernardo Haddock Lobo Goulart, MD, and colleagues found that response rate and progression-free survival were only moderately correlated with overall survival in first-line immunotherapy trials for metastatic non–small cell lung cancer (NSCLC). Bernardo Haddock Lobo Goulart, MD The pooled analysis comprised first-line randomized trials (including patients aged ≥ 18 years with metastatic squamous and nonsquamous
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
On October 16, 2023, pembrolizumab was approved for use with platinum-containing chemotherapy as neoadjuvant treatment and as single-agent adjuvant treatment in patients with resectable (tumors ≥ 4 cm or node-positive) non–small cell lung cancer (NSCLC). 1 Approval was based on findings in the double-blind multicenter KEYNOTE-671 trial (ClinicalTrials.gov identifier NCT03425643). In this study, 797 patients with previously untreated and resectable stage II, IIIA, or IIIB (N2) NSCLC were randomly assigned
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
On October 16, 2023, pembrolizumab was approved for use with platinum-containing chemotherapy as neoadjuvant treatment and as single-agent adjuvant treatment in patients with resectable (tumors ≥ 4 cm or node-positive) non–small cell lung cancer (NSCLC). 1 Approval was based on findings in the double-blind multicenter KEYNOTE-671 trial (ClinicalTrials.gov identifier NCT03425643). In this study, 797 patients with previously untreated and resectable stage II, IIIA, or IIIB (N2) NSCLC were randomly assigned
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
As reported in the Journal of Clinical Oncology by Tan et al, the phase III CANOPY-1 trial has shown no survival benefits with the addition of canakinumab to first-line pembrolizumab plus chemotherapy in patients with advanced/metastatic non–small cell lung cancer (NSCLC) without EGFR or ALK mutations. As noted by the investigators, canakinumab, a human monoclonal anti–interleukin (IL)-1β antibody, may enhance the activity of PD-L1 inhibitors and chemotherapy via inhibition of protumor inflammation. In
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Adding Tiragolumab to Atezolizumab and Chemotherapy in Previously Untreated Extensive-Stage SCLC - The ASCO Post - 5 month(s) ago
As reported in the Journal of Clinical Oncology by Charles M. Rudin, MD, PhD, and colleagues, the phase III SKYSCRAPER-02 trial showed no progression-free or overall survival benefit with the addition of the T-cell immunoglobulin and ITM domain (TIGIT) inhibitor tiragolumab to atezolizumab and chemotherapy in patients with previously untreated extensive-stage small cell lung cancer (SCLC). The double-blind trial included 490 patients from sites in 23 countries. They were randomly assigned between
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
Neoadjuvant Chemoimmunotherapy in Patients With Early-Stage NSCLC https://t.co/k3EN1rW0id #LCSM #lungcancer #immunotherapy #oncology